MCID: SHR001
MIFTS: 52

Short Bowel Syndrome

Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Short Bowel Syndrome

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome 11 19 58 75 53 43 14 71 33
Short Gut Syndrome 11 33
Secondary Short Bowel Syndrome 33
Acquired Short Bowel Syndrome 11
Short Bowel Nos 33

Characteristics:


Prevelance:

1-9/100000 (Europe) 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 11 DOID:10605
MeSH 43 D012778
NCIt 49 C99059
SNOMED-CT 68 204768009
MESH via Orphanet 44 D012778
UMLS via Orphanet 72 C0036992
Orphanet 58 ORPHA104008
ICD11 33 780637678
UMLS 71 C0036992

Summaries for Short Bowel Syndrome

GARD: 19 Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of Short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue.

MalaCards based summary: Short Bowel Syndrome, also known as short gut syndrome, is related to congenital short bowel syndrome and intestinal pseudo-obstruction, and has symptoms including pain, postoperative and postoperative nausea and vomiting. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors). The drugs Ursodeoxycholic acid and Plasminogen have been mentioned in the context of this disorder. Affiliated tissues include small intestine, kidney and liver, and related phenotypes are homeostasis/metabolism and nervous system

Orphanet: 58 Short bowel syndrome is an intestinal failure due to either a congenital defect, intestinal infarction or extensive surgical resection of the intestinal tract that results in a functional small intestine of less than 200cm in length and is characterized by diarrhea, nutrient malabsoption, bowel dilation and dysmobility.

Disease Ontology: 11 An intestinal disease that is characterized by a reduced ability to absorb nutrients due to the physical loss or the loss of function of a portion of the small and/or large intestine.

Wikipedia: 75 Short bowel syndrome (SBS, or simply short gut) is a rare malabsorption disorder caused by a lack of... more...

Related Diseases for Short Bowel Syndrome

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome Primary Short Bowel Syndrome
Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 congenital short bowel syndrome 33.2 FLNA CLMP
2 intestinal pseudo-obstruction 32.3 SST FLNA CLMP
3 volvulus of midgut 32.2 PYY GCG CCK
4 cholelithiasis 30.8 SST GAST CCK
5 ileus 30.5 SLC9A3 IL6 GLP2R GHRL
6 bone disease 30.5 IL6 IGF1 HGF FLNA
7 secretory diarrhea 30.4 SST SLC9A3 GAST
8 acute kidney failure 30.3 SLC9A3 IL6 HGF
9 meckel diverticulum 30.3 SST SLC15A1 GCG GAST
10 glucagonoma 30.3 SST GAST
11 carcinoid tumors, intestinal 30.2 SST GAST
12 hyperinsulinemic hypoglycemia 30.2 SST GCG GAST
13 gallbladder disease 30.2 SST PYY IL6 CCK
14 obstructive jaundice 30.2 TTR SST CCK
15 diarrhea 30.1 TTR SST SLC9A3 PYY NTS IL6
16 nutritional deficiency disease 30.1 TTR PYY IL6 IGF1 GHRL GH1
17 duodenal obstruction 30.1 SST CCK
18 colonic benign neoplasm 30.1 IL6 IGF1 GAST EGF
19 carcinoid syndrome 30.0 SST PYY NTS IGF1
20 esophagitis 30.0 NTS IL6 GAST
21 corneal ulcer 30.0 IL6 FGF7 EGF
22 gastroduodenal crohn's disease 30.0 GAST CCK
23 pancreatitis 29.9 SST IL6 GCG CCK
24 peptic ulcer disease 29.8 SST IL6 GHRL GAST CCK
25 fatty liver disease 29.8 IL6 IGF1 GHRL GCG
26 hepatic encephalopathy 29.8 TTR SST IL6
27 insulin-like growth factor i 29.7 SST IL6 IGF1 GHRL GH1 EGF
28 gastroparesis 29.7 SST GHRL GAST CCK
29 leptin deficiency or dysfunction 29.7 PYY IL6 IGF1 GHRL GCG CCK
30 hypoglycemia 29.7 SST IGF1 GHRL GH1 GCG GAST
31 mucositis 29.6 GLP2R GHRL GCG FGF7 EGF
32 hyperinsulinism 29.6 SST IGF1 GHRL GH1 GCG
33 chronic kidney disease 29.6 TTR IL6 IGF1 HGF GHRL
34 liver cirrhosis 29.5 TTR SST IL6 HGF GCG
35 protein-energy malnutrition 29.5 TTR IL6 IGF1 CCK
36 bowel dysfunction 29.4 PYY IL6 GLP2R GHRL GCG FGF7
37 kidney disease 29.4 TTR IL6 IGF1 HGF GHRL FGF7
38 arteriosclerosis 29.4 TTR IL6 HGF GHRL
39 dumping syndrome 29.3 SST PYY NTS GHRL GCG GAST
40 type 1 diabetes mellitus 29.3 SST IL6 IGF1 GHRL GH1 GCG
41 conn's syndrome 29.3 SST IL6 IGF1 GHRL GH1 GCG
42 cystic fibrosis 29.3 SLC9A3 NTS IL6 IGF1 EGF CCK
43 neuroendocrine tumor 29.2 SST NTS IGF1 GHRL GCG GAST
44 hypothyroidism 29.2 TTR SST IGF1 GH1
45 osteoporosis 29.2 IL6 IGF1 HGF GHRL GH1 EGF
46 celiac disease 1 29.1 PYY IL6 IGF1 GHRL GCG GAST
47 inflammatory bowel disease 29.0 SST SLC9A3 SLC15A1 PYY NTS IL6
48 deficiency anemia 29.0 TTR IL6 IGF1 GHRL GH1 GAST
49 body mass index quantitative trait locus 11 28.8 PYY NTS IL6 IGF1 GHRL GH1
50 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.5

Graphical network of the top 20 diseases related to Short Bowel Syndrome:



Diseases related to Short Bowel Syndrome

Symptoms & Phenotypes for Short Bowel Syndrome

UMLS symptoms related to Short Bowel Syndrome:


pain, postoperative; postoperative nausea and vomiting

GenomeRNAi Phenotypes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.21 AOC1 CCK CLMP EGF FGF7 FLNA
2 no effect GR00402-S-2 10.21 AOC1 CCK CLMP EGF FGF7 FLNA

MGI Mouse Phenotypes related to Short Bowel Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 AOC1 CCK CLMP FGF7 FLNA GAST
2 nervous system MP:0003631 10.14 AOC1 CCK FGF7 FLNA GH1 HGF
3 renal/urinary system MP:0005367 10.02 CCK CLMP FGF7 GCG GH1 IGF1
4 growth/size/body region MP:0005378 9.97 AOC1 CLMP EGF FLNA GCG GH1
5 adipose tissue MP:0005375 9.92 GH1 GHRL GLP2R IGF1 IL6 NTS
6 endocrine/exocrine gland MP:0005379 9.7 AOC1 CCK EGF GAST GCG GH1
7 digestive/alimentary MP:0005381 9.4 CLMP EGF FLNA GAST GCG GHRL

Drugs & Therapeutics for Short Bowel Syndrome

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
2
Plasminogen Approved Phase 4 9001-91-6
3
Carbamide peroxide Approved Phase 4 124-43-6
4
Apixaban Approved Phase 4 503612-47-3 10182969
5
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
6
L-Glutamine Approved, Investigational, Nutraceutical Phase 4 56-85-9 5961
7 Liver Extracts Phase 4
8
bilirubin Phase 4 635-65-4 5280352
9 Tissue Plasminogen Activator Phase 4
10 N-Methylaspartate Phase 4
11 Factor Xa Inhibitors Phase 4
12 Anticoagulants Phase 4
13 Serine Proteinase Inhibitors Phase 4
14 Antithrombins Phase 4
15 Antithrombin III Phase 4
16
Sitagliptin Phosphate Phase 4 654671-77-9
17 HIV Protease Inhibitors Phase 4
18 Dipeptidyl-Peptidase IV Inhibitors Phase 4
19
protease inhibitors Phase 4
20
D-Alanine Experimental, Nutraceutical Phase 4 302-72-7, 338-69-2, 56-41-7 101757026 602 71080 5950
21
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
22 Radiation-Protective Agents Phase 3
23 Protective Agents Phase 3
24
Pancrelipase Approved, Investigational Phase 2 53608-75-6 8519
25 Soybean oil, phospholipid emulsion Phase 2
26 Pancreatin Phase 2
27 Mitogens Phase 2
28 Cola Phase 2
29 Gastrointestinal Agents Phase 1, Phase 2
30 Antimetabolites Phase 2
31 Hypolipidemic Agents Phase 2
32 Anticholesteremic Agents Phase 2
33 Lipid Regulating Agents Phase 2
34 Cholestyramine Resin Phase 2
35
Amoxicillin Approved, Vet_approved Phase 1 26787-78-0 33613
36
Levofloxacin Approved, Investigational Phase 1 100986-85-4 149096
37
Levoleucovorin Approved, Experimental, Investigational Phase 1 68538-85-2, 58-05-9, 73951-54-9 149436 6006
38
Trimethoprim Approved, Vet_approved Phase 1 738-70-5 5578
39
Ofloxacin Approved Phase 1 82419-36-1 4583
40
Sulfamethoxazole Approved Phase 1 723-46-6 5329
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
42 Vaccines Phase 1
43 Immunologic Factors Phase 1
44 Antibiotics, Antitubercular Phase 1
45 Anti-Bacterial Agents Phase 1
46 Folic Acid Antagonists Phase 1
47 Folate Phase 1
48 Vitamin B9 Phase 1
49 Antiprotozoal Agents Phase 1
50 Antiparasitic Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome Completed NCT01974336 Phase 4 ursodeoxycholic acid
2 Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition Completed NCT02099084 Phase 4 Teduglutide;Placebo
3 A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN) Completed NCT03562130 Phase 4 Teduglutide
4 Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
5 Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project) Completed NCT01380366 Phase 4 Somatropin
6 Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition Recruiting NCT04344717 Phase 4 Apixaban single dose;Apixaban steady-state
7 An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome Terminated NCT00742157 Phase 4 Growth Hormone
8 The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome Terminated NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
9 Safety and Efficacy of SMOFlipid in Patients Intolerant to Intralipid. Withdrawn NCT03054948 Phase 4 SMOFLipid;Standard therapy
10 Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition Withdrawn NCT01818648 Phase 4 Exenatide;Placebo
11 A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT02682381 Phase 3 Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
12 A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Completed NCT00798967 Phase 3 teduglutide;placebo
13 A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS) Completed NCT03690206 Phase 3 glepaglutide;Placebo
14 A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT02980666 Phase 3 Teduglutide
15 A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT01952080 Phase 3 teduglutide
16 A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301 Completed NCT02954458 Phase 3 TED
17 Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome Completed NCT00169637 Phase 3 rhGH
18 A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome Completed NCT02340819 Phase 3 Teduglutide
19 A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome Completed NCT00930644 Phase 3 teduglutide
20 A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT03571516 Phase 3 Teduglutide
21 A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302 Completed NCT03268811 Phase 3 Teduglutide
22 A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed NCT00172185 Phase 3 teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
23 Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants Completed NCT02370251 Phase 2, Phase 3 Omegaven
24 A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT03663582 Phase 3 Teduglutide
25 A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Completed NCT00081458 Phase 3 Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
26 Cholestasis Reversal: Efficacy of IV Fish Oil Completed NCT00910104 Phase 2, Phase 3 Omegaven®
27 An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 Completed NCT03596164 Phase 3 Teduglutide
28 A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021 Completed NCT01560403 Phase 3 Teduglutide
29 A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003 Completed NCT02949362 Phase 3 Teduglutide
30 A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Apraglutide in Adult Subjects With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Recruiting NCT04627025 Phase 3 apraglutide
31 A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS) Recruiting NCT03905707 Phase 3 glepaglutide
32 A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation Recruiting NCT05027308 Phase 3 Teduglutide
33 An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Recruiting NCT05018286 Phase 3 Apraglutide
34 A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (SBS) Active, not recruiting NCT04991311 Phase 3 Glepaglutide
35 A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial Enrolling by invitation NCT04881825 Phase 3 Glepaglutide
36 Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Terminated NCT02266849 Phase 3 Loperamide;Placebo
37 A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection Terminated NCT02865122 Phase 2, Phase 3 NTRA-9620;Placebo
38 A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Withdrawn NCT02246816 Phase 3 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
39 A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Withdrawn NCT02242656 Phase 3 Opium Tincture USP Deodorized
40 Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial Unknown status NCT00793195 Phase 2 Intralipid 20%;SMOFlipid 20%
41 A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS) Unknown status NCT04379856 Phase 1, Phase 2 NM-002
42 Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Unknown status NCT01739517 Phase 2 Omegaven Therapy
43 A Phase 2 Trial Testing ZP1848 in Patients With SBS Completed NCT02690025 Phase 2 ZP1848
44 Use of Pancreatic Enzymes in Short Bowel Syndrome Completed NCT03097029 Phase 2 Pancreatic Enzyme
45 Diet/Growth Factor Mechanisms of Gut Adaptation Completed NCT00067860 Phase 2 recombinant human growth hormone
46 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Completed NCT01674478 Phase 2
47 A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen. Completed NCT03415594 Phase 1, Phase 2 FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue
48 A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency Completed NCT03408132 Phase 1, Phase 2 FE203799
49 Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure Recruiting NCT04604275 Phase 2 Sucrase
50 A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) Recruiting NCT04775706 Phase 2 HM15912 Active;Placebo

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Genetic Tests for Short Bowel Syndrome

Anatomical Context for Short Bowel Syndrome

Organs/tissues related to Short Bowel Syndrome:

MalaCards : Small Intestine, Kidney, Liver, Colon, Smooth Muscle, Bone, Bone Marrow

Publications for Short Bowel Syndrome

Articles related to Short Bowel Syndrome:

(show top 50) (show all 3859)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 53 62
20336592 2010
2
Medical management of pediatric intestinal failure. 53 62
20123270 2010
3
Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. 53 62
19773525 2010
4
Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. 53 62
19644131 2009
5
Short bowel syndrome: the role of GLP-2 on improving outcome. 53 62
19474717 2009
6
Ghrelin does not predict adaptive hyperphagia in patients with short bowel syndrome. 53 62
19176401 2009
7
Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? 53 62
19324585 2009
8
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. 53 62
19707516 2009
9
Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. 53 62
19590736 2009
10
GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. 53 62
18162829 2008
11
Review article: glucagon-like peptide 2--current applications and future directions. 53 62
17217448 2007
12
Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. 53 62
16830359 2006
13
Teduglutide for the treatment of short bowel syndrome. 53 62
16705029 2006
14
Glucagon-like peptide-2: update of the recent clinical trials. 53 62
16473060 2006
15
Dipeptidyl-peptidase IV in patients with short bowel syndrome. 53 62
16169633 2005
16
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. 53 62
16099790 2005
17
Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. 53 62
15961680 2005
18
A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. 53 62
15937810 2005
19
Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. 53 62
15388486 2005
20
Growth factors and trefoil peptides in gastrointestinal health and disease. 53 62
15525545 2004
21
Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. 53 62
15568286 2004
22
Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. 53 62
14965320 2004
23
[Glucagon-like peptides--synthesis, biological actions and some clinical implications]. 53 62
15803906 2004
24
Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. 53 62
14608100 2003
25
Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. 53 62
11987096 2002
26
Gut adaptation and the glucagon-like peptides. 53 62
11839727 2002
27
Biological actions and therapeutic potential of the glucagon-like peptides. 53 62
11832466 2002
28
Enhancement of intestinal growth and repair by growth factors. 53 62
11757811 2001
29
Cholecystokinin (CCK) secretion in patients with severe short bowel syndrome (SSBS). 53 62
11330425 2001
30
Glucagon-like peptide 2. 53 62
11297614 2001
31
Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. 53 62
10653491 2000
32
Epidermal growth factor and the short bowel syndrome. 53 62
10483910 1999
33
Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin. 53 62
10482697 1999
34
Clinical use of growth hormone and glutamine in short bowel syndrome. 53 62
10488599 1999
35
Epidermal growth factor stimulates the recovery of glucose absorption after small bowel transplantation. 53 62
9878331 1998
36
Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome. 53 62
9856891 1998
37
Epidermal growth factor selectively enhances functional enterocyte adaptation after massive small bowel resection. 53 62
9070188 1997
38
Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. 53 62
8862081 1996
39
Epidermal growth factor improves intestinal adaptation during somatostatin administration in vivo. 53 62
8661191 1996
40
Potential indications for octreotide in gastroenterology: summary of workshop. 53 62
8359570 1993
41
Somatostatin and its analogs in the short bowel syndrome. 53 62
1363486 1992
42
Aminoguanidine blocks intestinal diamine oxidase (DAO) activity and enhances the intestinal adaptive response to resection in the rat. 53 62
2124566 1990
43
Generation of Porcine Ileum Through Spring-Mediated Mechanical Distraction. 62
36037614 2022
44
In Vivo Intestinal Research Using Organoid Transplantation. 62
36450523 2022
45
Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects. 62
36323988 2022
46
Motility disorders in children with intestinal failure: a national tertiary referral center experience. 62
36114865 2022
47
Gastroschisis: a systematic review of diagnosis, prognosis and treatment. 62
33899664 2022
48
The role of gastrostomy feeding during intestinal rehabilitation for children with short bowel syndrome. 62
36462084 2022
49
Crohn's disease and short bowel syndrome. 62
35767069 2022
50
[WAYS TO SOLVE THE PROBLEM OF HOME PARENTERAL NUTRITION IN PATIENTS WITH SHORT BOWEL SYNDROME]. 62
36385073 2022

Variations for Short Bowel Syndrome

Expression for Short Bowel Syndrome

Search GEO for disease gene expression data for Short Bowel Syndrome.

Pathways for Short Bowel Syndrome

Pathways related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 SST PYY NTS GLP2R GHRL GCG
2
Show member pathways
13.28 SST PYY NTS GLP2R GHRL GCG
3
Show member pathways
13.2 EGF FGF7 GH1 HGF IGF1 IL6
4
Show member pathways
13.15 IL6 IGF1 HGF GH1 FLNA FGF7
5
Show member pathways
12.96 IL6 IGF1 HGF GH1 FGF7 EGF
6
Show member pathways
12.92 IL6 IGF1 HGF GH1 FGF7 EGF
7 12.88 SST PYY NTS IL6 IGF1 HGF
8
Show member pathways
12.78 EGF FGF7 GH1 HGF IGF1 IL6
9 12.53 IL6 IGF1 HGF FGF7 EGF
10
Show member pathways
12.47 IL6 IGF1 HGF GH1 FGF7 EGF
11
Show member pathways
12.46 IL6 IGF1 HGF GH1 FGF7 EGF
12
Show member pathways
12.2 IL6 IGF1 HGF GH1 FGF7 EGF
13 12.16 IGF1 HGF FLNA EGF
14
Show member pathways
12.04 IGF1 GHRL GH1 GCG
15 11.77 IL6 IGF1 EGF
16 11.68 IL6 IGF1 HGF FGF7 EGF
17 11.65 IL6 HGF EGF
18 11.49 EGF FGF7 GH1 HGF IGF1 IL6
19 11.24 IL6 IGF1 HGF EGF
20 11.15 IL6 IGF1 HGF FGF7 EGF
21 10.92 IL6 IGF1 EGF
22 10.84 IL6 IGF1 HGF GH1 FGF7 EGF
23 10.33 PYY GCG

GO Terms for Short Bowel Syndrome

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.1 AOC1 CCK EGF FGF7 GAST GCG
2 extracellular region GO:0005576 9.83 AOC1 CCK EGF FGF7 FLNA GAST
3 brush border GO:0005903 9.63 SLC9A3 SLC15A1 FLNA

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.18 IL6 IGF1 HGF GHRL GCG FLNA
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.86 EGF GH1 HGF IGF1
3 epithelial to mesenchymal transition GO:0001837 9.85 IGF1 HGF FLNA
4 positive regulation of MAPK cascade GO:0043410 9.85 IL6 IGF1 HGF GHRL EGF
5 epithelial cell proliferation GO:0050673 9.83 HGF FGF7 EGF
6 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.62 HGF FGF7
7 myoblast proliferation GO:0051450 9.43 IGF1 HGF FGF7
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.36 IL6 IGF1 HGF GH1 FGF7 EGF

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.73 IL6 IGF1 HGF GH1 FGF7 EGF
2 neuropeptide hormone activity GO:0005184 9.63 PYY NTS CCK
3 hormone activity GO:0005179 9.55 TTR SST PYY IGF1 GHRL GH1

Sources for Short Bowel Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....